Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTNASDAQ:FRTXNASDAQ:GRTXNASDAQ:GTBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTConduit Pharmaceuticals$0.55-3.1%$0.88$0.51▼$350.00$3.63M2.371.59 million shs591,409 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.93$0.03▼$1.03$5.59M0.542,709 shs2,402 shsGRTXGalera Therapeutics$0.02-3.2%$0.03$0.02▼$0.23$1.80M1.94119,132 shs129 shsGTBPGT Biopharma$2.30+0.9%$2.33$1.72▼$10.66$5.96M1.31579,535 shs8,761 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTConduit Pharmaceuticals0.00%-9.29%-36.80%-82.95%-99.82%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%+35.51%+2.74%GRTXGalera Therapeutics0.00%-1.20%-24.00%-43.48%-86.73%GTBPGT Biopharma0.00%+0.44%-5.00%+11.76%-31.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDTConduit Pharmaceuticals0.4301 of 5 stars0.02.00.00.02.51.70.0FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma3.4777 of 5 stars3.85.00.00.03.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTConduit Pharmaceuticals 4.00Strong BuyN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00378.26% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTConduit PharmaceuticalsN/AN/AN/AN/A($0.62) per shareN/AFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AGTBPGT BiopharmaN/AN/AN/AN/A$5.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTConduit Pharmaceuticals-$540K-$39.33N/A∞N/AN/AN/A-328.67%5/13/2025 (Estimated)FRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AGRTXGalera Therapeutics-$59.08M-$0.35N/A∞N/AN/AN/A-99.34%N/AGTBPGT Biopharma-$7.60M-$7.00N/AN/AN/AN/A-257.47%-131.09%5/13/2025 (Estimated)Latest GRTX, GTBP, CDT, and FRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025GTBPGT Biopharma-$0.64N/AN/AN/AN/AN/A3/28/2025Q4 2024CDTConduit PharmaceuticalsN/A-$20.33N/A-$20.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTConduit PharmaceuticalsN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTConduit PharmaceuticalsN/A0.120.12FRTXFresh Tracks TherapeuticsN/AN/AN/AGRTXGalera TherapeuticsN/A9.749.74GTBPGT BiopharmaN/A1.451.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTConduit Pharmaceuticals3.29%FRTXFresh Tracks Therapeutics25.04%GRTXGalera Therapeutics50.77%GTBPGT Biopharma8.15%Insider OwnershipCompanyInsider OwnershipCDTConduit Pharmaceuticals30.93%FRTXFresh Tracks Therapeutics0.23%GRTXGalera Therapeutics12.90%GTBPGT Biopharma10.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTConduit Pharmaceuticals36.66 million710,000Not OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableGTBPGT Biopharma82.54 million1.99 millionNo DataGRTX, GTBP, CDT, and FRTX HeadlinesRecent News About These CompaniesGT Biopharma Issues Warrant to Cytovance for Services RenderedApril 6, 2025 | investing.comGT Biopharma files to sell 625,283 shares of common stock for holdersMarch 7, 2025 | markets.businessinsider.comGT Biopharma to Participate in the 10th Anniversary of the Innate Killer SummitMarch 4, 2025 | markets.businessinsider.comGT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy TweakFebruary 26, 2025 | msn.comGT Biopharma, Inc. Announces Exercise of Warrants for Common Stock, Anticipating $0.7 Million in Gross ProceedsFebruary 25, 2025 | quiverquant.comGT Biopharma Announces Exercise of WarrantsFebruary 25, 2025 | globenewswire.comGT Biopharma could report Phase 1 trial data later this year, says Roth MKMFebruary 25, 2025 | markets.businessinsider.comGT Biopharma Announces Request for Withdrawal of Form S-1 Registration StatementFebruary 25, 2025 | markets.businessinsider.comGT Biopharma announces first patient dosed in Phase 1 trial of GTB-3650January 27, 2025 | markets.businessinsider.comGT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic MalignanciesJanuary 27, 2025 | manilatimes.netGT Biopharma Inc (GTBP) Stock: Surpassing Expectations in the Market?January 14, 2025 | bovnews.comGT Biopharma Inc (GTBP) Stock Dilemma: A Surge That Has Everyone Talking—What’s the Real Story?December 24, 2024 | bovnews.comGT Biopharma files automatic mixed securities shelfDecember 23, 2024 | msn.comGT Biopharma initiated with a Buy at Roth MKMDecember 3, 2024 | markets.businessinsider.comRoth MKM Initiates Coverage of GT Biopharma (GTBP) with Buy RecommendationDecember 3, 2024 | msn.comGT Biopharma Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comGT Biopharma (NASDAQ:GTBP) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comGT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceSeptember 26, 2024 | globenewswire.comGT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024September 24, 2024 | globenewswire.comGT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 15, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTX, GTBP, CDT, and FRTX Company DescriptionsConduit Pharmaceuticals NASDAQ:CDT$0.55 -0.02 (-3.11%) Closing price 04:00 PM EasternExtended Trading$0.55 +0.00 (+0.18%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Galera Therapeutics NASDAQ:GRTX$0.02 0.00 (-3.24%) As of 10:53 AM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.GT Biopharma NASDAQ:GTBP$2.30 +0.02 (+0.88%) Closing price 03:59 PM EasternExtended Trading$2.30 0.00 (0.00%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
